FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089278582> ?p ?o ?g. }

• W3089278582 abstract "Background The emergence of specific therapies for transthyretin cardiac amyloidosis (CA) warrants the need for a systematic review of the literature. Methods and Results A systematic review of the literature was conducted according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. A systematic search was performed on MEDLINE, PubMed, and Embase databases on November 29, 2019. Studies were selected based on the following predefined eligibility criteria: English‐language randomized controlled trials (RCTs), non‐RCTs, or observational studies, which included adult patients with variant/wild‐type transthyretin‐CA, assessed specific therapies for transthyretin‐CA, and reported cardiovascular outcomes. Relevant data were extracted to a predefined template. Quality assessment was based on National Institute for Health and Care Excellence recommendations (RCTs) or a checklist by Downs and Black (non‐RCTs). From 1203 records, 24 publications were selected, describing 4 RCTs (6 publications) and 16 non‐RCTs (18 publications). Tafamidis was shown to significantly improve all‐cause mortality and cardiovascular hospitalizations and reduce worsening in 6‐minute walk test, Kansas City Cardiomyopathy Questionnaire—Overall Summary score, and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) in variant/wild‐type transthyretin‐CA. Patisiran showed promising results in a subgroup analysis of patients with variant transthyretin‐CA, which have to be confirmed in RCTs. Inotersen showed conflicting results on cardiac imaging parameters. The one study on AG10 had only a 1‐month duration and cardiovascular end points were exploratory and limited to cardiac biomarkers. Limited evidence from noncomparative single‐arm small non‐RCTs existed for diflunisal, epigallocatechin‐3‐gallate (green tea extract), and doxycycline+tauroursodeoxycholic acid/ursodeoxycholic acid. Conclusions This systematic review of the literature supports the use of tafamidis in wild‐type and variant transthyretin‐CA. Novel therapeutic targets including transthyretin gene silencers are currently under investigation." @default.
• W3089278582 created "2020-10-01" @default.
• W3089278582 creator A5003744755 @default.
• W3089278582 creator A5005592745 @default.
• W3089278582 creator A5031484534 @default.
• W3089278582 creator A5040049502 @default.
• W3089278582 creator A5054859474 @default.
• W3089278582 creator A5070354299 @default.
• W3089278582 creator A5075614922 @default.
• W3089278582 creator A5076137295 @default.
• W3089278582 date "2020-10-06" @default.
• W3089278582 modified "2023-10-16" @default.
• W3089278582 title "Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence‐Based Recommendations" @default.
• W3089278582 cites W1488540650 @default.
• W3089278582 cites W1782332202 @default.
• W3089278582 cites W1965038358 @default.
• W3089278582 cites W1968608825 @default.
• W3089278582 cites W1988802619 @default.
• W3089278582 cites W1996927016 @default.
• W3089278582 cites W2053660767 @default.
• W3089278582 cites W2114488753 @default.
• W3089278582 cites W2160930399 @default.
• W3089278582 cites W2194640608 @default.
• W3089278582 cites W2264916680 @default.
• W3089278582 cites W2266690651 @default.
• W3089278582 cites W2297947990 @default.
• W3089278582 cites W2465483060 @default.
• W3089278582 cites W2514539338 @default.
• W3089278582 cites W2566731945 @default.
• W3089278582 cites W2795771604 @default.
• W3089278582 cites W2809989268 @default.
• W3089278582 cites W2810909862 @default.
• W3089278582 cites W2888036721 @default.
• W3089278582 cites W2912435333 @default.
• W3089278582 cites W2921617821 @default.
• W3089278582 cites W2921829640 @default.
• W3089278582 cites W2946559203 @default.
• W3089278582 cites W2964332752 @default.
• W3089278582 cites W2971824914 @default.
• W3089278582 cites W2983833521 @default.
• W3089278582 cites W3006028248 @default.
• W3089278582 cites W4239270357 @default.
• W3089278582 cites W4294215472 @default.
• W3089278582 doi "https://doi.org/10.1161/jaha.120.016614" @default.
• W3089278582 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7792401" @default.
• W3089278582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32969287" @default.
• W3089278582 hasPublicationYear "2020" @default.
• W3089278582 type Work @default.
• W3089278582 sameAs 3089278582 @default.
• W3089278582 citedByCount "6" @default.
• W3089278582 countsByYear W30892785822021 @default.
• W3089278582 countsByYear W30892785822023 @default.
• W3089278582 crossrefType "journal-article" @default.
• W3089278582 hasAuthorship W3089278582A5003744755 @default.
• W3089278582 hasAuthorship W3089278582A5005592745 @default.
• W3089278582 hasAuthorship W3089278582A5031484534 @default.
• W3089278582 hasAuthorship W3089278582A5040049502 @default.
• W3089278582 hasAuthorship W3089278582A5054859474 @default.
• W3089278582 hasAuthorship W3089278582A5070354299 @default.
• W3089278582 hasAuthorship W3089278582A5075614922 @default.
• W3089278582 hasAuthorship W3089278582A5076137295 @default.
• W3089278582 hasBestOaLocation W30892785821 @default.
• W3089278582 hasConcept C121157162 @default.
• W3089278582 hasConcept C126322002 @default.
• W3089278582 hasConcept C15744967 @default.
• W3089278582 hasConcept C168563851 @default.
• W3089278582 hasConcept C17744445 @default.
• W3089278582 hasConcept C180747234 @default.
• W3089278582 hasConcept C189708586 @default.
• W3089278582 hasConcept C199539241 @default.
• W3089278582 hasConcept C23131810 @default.
• W3089278582 hasConcept C2777607188 @default.
• W3089278582 hasConcept C2778201750 @default.
• W3089278582 hasConcept C2779356329 @default.
• W3089278582 hasConcept C2779473830 @default.
• W3089278582 hasConcept C2779951007 @default.
• W3089278582 hasConcept C71924100 @default.
• W3089278582 hasConcept C95190672 @default.
• W3089278582 hasConcept C98274493 @default.
• W3089278582 hasConceptScore W3089278582C121157162 @default.
• W3089278582 hasConceptScore W3089278582C126322002 @default.
• W3089278582 hasConceptScore W3089278582C15744967 @default.
• W3089278582 hasConceptScore W3089278582C168563851 @default.
• W3089278582 hasConceptScore W3089278582C17744445 @default.
• W3089278582 hasConceptScore W3089278582C180747234 @default.
• W3089278582 hasConceptScore W3089278582C189708586 @default.
• W3089278582 hasConceptScore W3089278582C199539241 @default.
• W3089278582 hasConceptScore W3089278582C23131810 @default.
• W3089278582 hasConceptScore W3089278582C2777607188 @default.
• W3089278582 hasConceptScore W3089278582C2778201750 @default.
• W3089278582 hasConceptScore W3089278582C2779356329 @default.
• W3089278582 hasConceptScore W3089278582C2779473830 @default.
• W3089278582 hasConceptScore W3089278582C2779951007 @default.
• W3089278582 hasConceptScore W3089278582C71924100 @default.
• W3089278582 hasConceptScore W3089278582C95190672 @default.
• W3089278582 hasConceptScore W3089278582C98274493 @default.
• W3089278582 hasIssue "19" @default.
• W3089278582 hasLocation W30892785821 @default.
• W3089278582 hasLocation W30892785822 @default.
• W3089278582 hasLocation W30892785823 @default.

• next